MIRM · Mirum Pharmaceuticals, Inc.
Market Cap
$6.48B
Shares
64.93M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$97.46
Open$99.43
Day$96.55–100.06
52W close$64.10–128.57
Avg vol 30d666K
Short int6.5M · 10.0% float · 7.3d
Short vol68%
Last earningsAug 5, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 4, 2026
Est · unconfirmed
· in 9 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 5, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Neutral
Momentum
Neutral
Sentiment
Bullish
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 14.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+2%
above
Price vs 50-day avg
−12%
below
RSI (14)
41
neutral
MACD trend
Positive
52-week position
52%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−8%
trailing
6-month return
+10%
trailing
YTD return
+23%
this year
Relative strength
−4%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $110 › 200d $95 — 50d above 200d
Institutional flow
Accumulating
+5% holders QoQ · +62 funds added
Insider flow
Distributing
Net -$4.4M over 90 days · 100% sells
Short interest
Falling
9.99% of float · ▼ -4.9% MoM · 7.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
331 holders — near 3-yr high, broad support
Squeeze score
71
high risk · 0–100
Fundamentals
EPS growth
+75%
Y/Y
Free cash flow
$54.9M
Quant / Vol
risk profile
Volatility
46%
annualized · 1-yr
Max drawdown
−27%
past year
ATR
4.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 5, 2026
Net product sales
· 2026
$680M – $700M
Prior guidance
period ended
· from the 8-K filed Nov 4, 2025
Revenue guidance
· Full year 2025
$500M – $510M
Guided vs delivered
· last 2 settled
Revenue guidance
Full year 2025
guided $500M – $510M
$521.31M
Beat +3.2%
Global net product sales
2024
guided $330M – $335M
$336.89M
Beat +1.3%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+2%
Bullish
Price vs 50-day avg
−12%
Bearish
RSI (14)
41
Neutral
MACD trend
Positive
Bullish
52-week position
52%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $110 › 200d $95 — 50d above 200d
Institutional flow
Accumulating
+5% holders QoQ · +62 funds added
Insider flow
Distributing
Net -$4.4M over 90 days · 100% sells
Short interest
Falling
9.99% of float · ▼ -4.9% MoM · 7.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
331 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $64
Now $97 · 52%
Range high $129
vs 200-day avg +2%
vs 50-day avg -12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Bile Acid Medicines net product sales | $47.5M | Q2 2026 | +19.9% |
|
|
|||
| CHOLBAM and CTEXLI net product sales | $47.52M | FY2026 Q2 | +19.9% |
|
|
|||
| CHOLBAM and CTEXLI net sales | $47.52M | FY2026 Q2 | +19.9% |
|
|
|||
| global net product sales | $176.2M | Q2 2026 | +37.9% |
|
|
|||
| LIVMARLI net product sales | $128.7M | Q2 2026 | — |
|
|
|||
| LIVMARLI net sales | $128.72M | FY2026 Q2 | +46.0% |
|
|
|||
| Total net product sales | $176.24M | FY2026 Q2 | +37.9% |
|
|
|||
| countries with commercial access | 33 | full year 2025 | — |
| Annual Net Product Sales | $179M | FY2025E | — |
| Cash, cash equivalents and investments | $392M | as of December 31, 2025 | — |
| LIVMARLI US net product sales | $243M | full-year 2025 | — |
| LIVMARLI YoY Growth | 69% | FY2025E | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MIRM
this stock
Mirum Pharmaceuticals, Inc.
|
$6.48B | +23.4% | +54.7% | — | 10.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +19.5% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.27B | +2.9% | +20.8% | 19.6 | 2.3% |
|
ARGX
Argenx SE
|
$63.63B | +21.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.23B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MIRM | +1.2% | -8.0% | +9.8% | -8.0% | +23.4% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | +0.7% | -11.0% | -3.7% | -11.0% | +10.6% |
Key facts
CIK
1759425
CUSIP
604749101
13F (30d)
268 filings
266 filers
Visit website
Investor relations